Purpose: Report our institutional experience with pleomorphic xanthoastrocytoma (PXA) to contribute to limited data on optimal management.
Methods: Patients with pathologically confirmed PXA treated at our institution between 1990 and 2019 were identified. Demographic information, tumor grade, treatment variables, and clinical outcomes were collected from patient charts.